Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Crit Care Med. 2010 Aug;38(8 Suppl):S345-51. doi: 10.1097/CCM.0b013e3181e6cbc5.
Multidrug-resistant Gram-negative bacteria pose a serious and rapidly emerging threat to patients in healthcare settings and are especially prevalent and problematic in intensive care units. Few antimicrobial treatment options remain for patients infected with the most resistant of these pathogens. Recent data shed light on the extent of the multidrug-resistant Gram-negative problem and suggest potential strategies to prevent transmission and improve clinical outcomes. This review examines the clinical impact and epidemiology of multidrug-resistant Gram-negative bacteria as a cause of healthcare-associated infections in critically ill patients, discusses issues regarding detection and recognition of these organisms, and reviews recommended methods to prevent patient-to-patient transmission of these formidable pathogens. Recent guidance from the Centers for Disease Control and Prevention for detection and control of carbapenemase-producing Enterobacteriaceae is discussed, along with potential strategies to optimize the existing antimicrobial treatment options for patients with multidrug-resistant Gram-negative infections.
多重耐药革兰氏阴性菌对医疗机构中的患者构成了严重且迅速出现的威胁,尤其是在重症监护病房中更为普遍和棘手。对于感染这些最耐药病原体的患者,可用的抗菌治疗选择很少。最近的数据揭示了多重耐药革兰氏阴性菌问题的严重程度,并提出了潜在的策略来预防传播和改善临床结果。这篇综述检查了多重耐药革兰氏阴性菌作为重症监护患者医疗相关感染的原因的临床影响和流行病学,讨论了关于检测和识别这些生物体的问题,并回顾了预防这些强大病原体在患者之间传播的推荐方法。还讨论了疾病预防控制中心最近针对产碳青霉烯酶肠杆菌科的检测和控制的指导意见,以及优化治疗多重耐药革兰氏阴性菌感染患者的现有抗菌治疗选择的潜在策略。